A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are either time-consuming or lack detection sensitivity. Dianthus NT.23PicoDuo utilizes a biophysical detection method for fast, precise and confident hit identification, target validation and lead optimization. An example of single-dose and affinity screening against histone methylase G9a, known to be associated with cancer onset, will be discussed.
Most recent content
42:49Quality control during membrane protein purification for cryo-EM
In this webinar Dr. Melanie McDowell, Research Group Leader at the MPI of Biophysics outlines bottlenecks associated with membrane protein purification for cryo EM and strategies to overcome them
53:00Cube x NanoTemper Webinar Series – Episode 2: Optimization of Membrane Proteins for Cryo-EM with Prometheus Panta
Explore a comprehensive, data-driven workflow—rooted in real-world results—combining the NativeMP platform with Prometheus Panta.
31:28Watch this webinar to discover how Dr. Marius Müller from Johnson & Johnson Innovative Medicine, uses nanoDSF, a high-throughput method that assesses protein stability, for drug substance ID testing.
43:09Learn about technologies and instruments that maintain membrane protein stability and allow structural abd affinity screening studies in their natural lipid environment.
21:30Fluorescence-Based Technologies for Binding Affinity Studies: Benefits and Labeling Best Practices
Regardless of fluorescence technology (i.e Spectral Shift, TRIC, or FRET), optimizing your labeling strategy is essential to minimize impact on the functionality and ensure accurate Kd measurements
26:58Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.
18:36Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equi
16:24De-risk your antibody characterization workflows with high-quality, multi-parameter stability data from Prometheus Panta
Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.
22:59Biologics Formulation: Select optimal buffer conditions with multi-parameter stability characterization from Prometheus Panta
Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability characterization from Prometheus Panta, a tool to collect thermal and colloidal data while saving
17:08Assess the impact of bioconjugation with multi-parameter stability characterization
Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.
19:07How stability prediction experiments give you confidence in your ADCs
For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.
20:31The power of Monolith X for Characterizing GPCRs: Accelerating Binding Affinity Measurements
To understand signaling pathways, Spectral Shift technology allows for accurate bindings affinity measurements of membrane proteins like GPCRs in close to native conditions.
14:18Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap
11:48Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors
MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study
38:20Conversation: How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation
Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps
19:16How to mitigate risk during ADC development with multi-parameter stability characterization
To assess the developability properties of antibody-drug conjugates (ADCs) learn about multi-parameter characterization of thermal and colloidal stability with Prometheus Panta using nanoDSF and DLS
38:31nanoDSF for biologics: How to interpret thermal unfolding profiles for your different applications
Thermal stability screening is a common approach used to study the developability of a wide range of protein-based therapeutics. Among the different technologies available to perform thermal stability
24:28Thermal stability measurements for biologics developability profiling
Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.
22:23Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
8:38Explore Prometheus Panta – Frequently asked questions about stability profiling experiments
In this video, Nathan Wallace, Application Specialist at NanoTemper, addresses common questions about experimental design for developability profiling and the operation of Prometheus Panta.